A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is Associated with Immunotherapy Response
New measure of tumour mutational burden based on genomic regions unlikely to undergo loss
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients with BRAF V600E-mutated Colorectal Cancer
Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition
FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC
Evidence for efficacy is based on the results from the KEYNOTE-091 study
Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint Inhibitors in the Treatment of Advanced NSCLC, Particularly Among the Older Patients
Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age
EMA Recommends Extension of Indications for Darolutamide
New indication concerns the treatment of patients with metastatic hormone-sensitive prostate cancer in combination with docetaxel and androgen deprivation therapy
Prognostic Role of ctDNA in Patients with Surgically Resectable Colorectal Cancer
Findings from the GALAXY, an observational arm of the ongoing CIRCULATE-Japan study
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma
Evidence for efficacy is based on the results from the SEQUOIA and ALPINE studies
Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable Colon Cancer, Producing Marked Histopathologic Downstaging and Disease Control
Findings from the FOxTROT study
FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer
Evidence for efficacy is based on the results from the MOUNTAINEER study
Efficacy and Safety of Futibatinib in Patients with Previously Treated Intrahepatic Cholangiocarcinoma Harbouring FGFR2 Fusions or Other Rearrangements
Findings from the FOENIX-CCA2 study
When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic and Predictive Value of RNA Sequencing–Based Immune Signatures is Superior
Findings from a correlative analysis of the CALGB 40601 and PAMELA studies in patients with early HER2-positive breast cancer
A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations in An Observational Pancancer Setting
Findings highlight a complex relationship between immune-related adverse events and clinical outcome